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1. Introduction 
Valvular aortic stenosis (AS) produces a slowly progressive obstruction in left ventricular 
outflow track. Aortic valve replacement is warranted when symptoms or left ventricular 
dysfunction develop, which happen when the valvular stenosis is hemodynamically 
significant. Among the three main causes of valvular AS (congenital, rheumatic or 
degenerative), degenerative AS is the most prevalent in the older population, and due to the 
aging population it is the most frequent cause of valve replacement in western countries. 
Currently it is responsible for most valve replacements performed in Europe, and there is a 
steady increase of this disease and its social significance (Iun et al., 2003). 
Degenerative or calcific aortic valve disease is characterized by aortic valve leaflet thickening 
and calcification of the aortic valve, usually in an anatomically normal trileaflet valve. Several 
studies have demonstrated an association between degenerative AS and cardiovascular risk 
factors for atherosclerosis, such as hypercholesterolemia, hypertension, tobacco, the metabolic 
syndrome, etc, and as a consequence a similar pathobiologic process has been suggested for 
degenerative AS and atherosclerosis (Stewart et al., 1997; Agmon et al., 2001). But although 
there are many similarities between these two diseases, the differences are also significant. 
The pathobiology of aortic valve calcification comprises three main processes: lipid 
accumulation, inflammation and calcification. Accumulation and oxidation of LDL-
cholesterol particles, T-lymphocytes, macrophages, and production of inflammatory 
mediators such as interleukin-1-beta and transforming growth factors beta-1 have been 
observed at tissue level in the aortic leaflets of patients with degenerative AS. Angiotensin 
converting enzyme production has also been detected at valvular level in these patients. In 
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later stages of the disease, active cartilage and bone formation have also been reported 
(Mohler et al., 2001; Freeman et al., 2005).  All these findings suggest that degenerative AS is 
an active process instead of a passive “wear and tear” phenomenon as it has been 
considered for decades. 
Although hypercholesterolemia has been pointed out as a risk factor for degenerative AS, its 
relationship with this disease is far from being clear. The similarities between the pathobiology 
of degenerative AS and atherosclerosis suggested that statins could decrease the progression 
of degenerative AS and help avoiding its clinical consequences as has been demonstrated in 
coronary artery disease. However, the last trials that analysed moderate-to-severe 
degenerative AS have failed to demonstrate any benefit of statins in the clinical evolution of 
this disease (Cowell et al., 2005; Chan et al., 2010), despite having demonstrated, in the SEAS 
trial (Rossed et al., 2008), a reduction of some coronary events with the reduction in LDL 
cholesterol. Therefore, once significant degenerative AS has progressed cholesterol does not 
appear to be longer related with the process, which is opposed to what has been observed in 
atherosclerosis. This has also been suggested by the only trial performed in patients with mild 
degenerative AS, the RAAVE trial, in which rosuvastatin showed a mild positive impact of 
cholesterol reduction on the progression of degenerative AS as assessed by echocardiography 
(Moura et al., 2001). Taken together, this suggests that some risk factors can play a role only in 
the early stages of the disease, but once the calcification process starts to develop, the role 
played by the classical risk factors appears to wane, although the information so far available 
is somewhat contradictory (Walter et al., 2010). 
The conflicting information available makes it necessary to further study the 
pathophysiologic process of degenerative AS in order to unveil the basic mechanisms of the 
disease, a needed step in the process of developing reliable biomarkers of the disease as well 
as preventive therapies for it. Proteomics, a science aimed at discovering the proteins 
involved in the pathogenic process of diseases in an unbiased way, appears especially suited 
for studying the pathogenic processes involved in the development of degenerative AS. This 
chapter provides information about the different proteomics techniques for the AS study. 
We have begun to apply these methodologies to examine the physiological changes that 
accompany this pathology in a comprehensive manner. The techniques described in this 
chapter were optimized in our laboratory for the analysis of different kind of human 
samples. Data reported by our lab as well as by other authors will be presented to give the 
reader a wide perspective of the information available about the pathogenesis of this 
prevalent and clinically significant disease.  
2. AS plasma proteome 
At present, it is possible to perform a differential proteomic approach on a variety of 
biological samples, including cells, tissues or biological fluids (plasma, urine). In the context 
of biomarker discovery, biological fluids such as plasma or urine, represent the most logical 
compartment for investigation. 
Plasma is the best clinical sample in terms of diagnosis and prognosis, due to several 
advantages including its low cost, not invasive and easy access (Veenstra TD et al., 2005). 
Human plasma is a rich source of proteins and other metabolites which reflect the 
physiological or clinical status of patients. Since blood circulates throughout every organ 
and tissue of the body, it is expected to contain valuable information about the real 
physiological state of the organism. The protein concentration in plasma is tightly controlled 
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and, thus, variations can be considered as an indicator of the current state of health. 
Numerous biomedical/clinical proteomic studies have demonstrated that plasma protein 
levels reflect human physiological and pathological states and can be used for disease 
diagnosis and prognosis (Anderson NL et al., 2002).  
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Fig. 1. Human plasma proteome. A, The large dinamic range of protein concentrations in the 
human proteome represents a significant experimental challenge as technologies must be 
sensitive across nearly 12 orders of magnitude (a 1 trillionfold range) for comprehensive 
analysis and the development of biomarkers. B, Estimated concentration of plasma proteins 
(based in Anderson and Anderson, 2002 Molecular and cellular proteomics) 
However, the plasma proteome is very complex and presents a wide dynamic range of 
proteins  (more than 10 magnitude orders) what makes its proteomic analysis very 
challenging, because high-abundance proteins tend to mask those of lower abundance 
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(Anderson NL et al., 2005). In other words, only 20 major proteins comprise 99% of the 
plasma proteome and the rest of the proteins making up 1% of the plasma content (Figure 
1). Potential disease biomarkers could be present in low concentrations, and not be detected 
by the current proteomic techniques (Darde VM et al., 2010). Hence, it is essential to perform 
a pre-fractionation method. Cibacron Blue Dye and protein A/G columns have been used to 
effectively remove serum albumin and immunoglobulins from serum, allowing detection of 
proteins present at very low concentrations. Nowadays, the most common technique is the 
immunodepletion, which has been extensively used for the specific removal of the most 
abundant proteins, based on the action of specific antibodies (Zolotarjova N. et al., 2005 and 
Wang YY et al., 2003). Among these, Multiple Affinity Removal Columns (MARC) is the 
most effective method because it simultaneously removes multiple abundant proteins 
(Bjorhall K, et al., 2005 and Seam N et al., 2007).  
There are several affinity columns as MARS-6 or MARS-14 (Agilent Tecnologies) to deplete the 
6 or 14 more abundant proteins and even to deplete the 20 more abundant proteins with the 
Top-20 column (Sigma). In any case, there has been concerned regarding whether less 
abundant plasma proteins are removed jointly with albumin and other commonly depleted 
proteins by “nonspecific” binding (albuminome) (Yocum AK, et al., 2005 and Granger J et al., 
2005). To save this problem, the combinatorial peptide ligand libraries (CPLL) have been 
proposed as an alternative method (Righetti PG et al., 2006 and Sihlbom C et al., 2008). This 
methodology was designed for sample equalization and it is used to analyze the "low-
abundance proteome" in association with mass spectrometry (MS). CPLL have been recently 
used in plasma analysis to reduce their complexity, hence the most abundant plasma proteins 
would saturate all its corresponding hexapeptides in peptide library and the excess will be 
eliminated, while the less abundant plasma proteins will be more represented and more 
accessible to the differential analysis of protein expression (Righetti P G et al., 2006). 
Until now, the main approximation to plasma analysis has been the two-dimensional gel 
electrophoresis (2-DE), although it presents several limitations, since highly acidic or 
hydrophobic proteins and those with the highest or the smallest molecular weight in the 
sample may not be represented. However, 2-DE allows detecting changes in specific 
isoforms and, in general, approximately 1000-2000 protein spots can be visualized on a gel 
(Tannu NS and Hemby SE. 2006). Gel based approaches have enabled important advances 
in measurement of protein expression alterations in normal and diseases states. Moreover, 
new more sensitive fluorescence probes (Sipro Ruby, Cy2, Cy3 and Cy5) have been designed 
to improve spots detection and identification from 2-DE gels, improving hugely the 
“classical” silver stain. A methodological advance in 2-DE has been the 2-D Fluorescence 
Difference Gel Electrophoresis (2D-DIGE) (GE Healthcare). 2D-DIGE is based on direct 
labeling of lysine groups on proteins with cyanine CyDye DIGE Fluor minimal dyes before 
isoelectric focusing, enabling the labeling of 2-3 samples per gel with different dyes. This 
capability minimizes spot pattern variability and the number of gels by experiment 
providing a simple, accurate and reproducible spot matching. This is achieved by inclusion 
of an internal standard for every spot in every 2-DE gel, providing with experimental 
reproducibility and the highest accuracy in protein ratio measurements. In this way, the 
individual protein data from the control and diseased samples (Cy3 or Cy5) are normalized 
against the internal standard sample (Cy2 dye-labeled), Cy5:Cy2 and Cy3:Cy2.  
To avoid 2-DE limitations, new alternatives have been developed, the most successful is 
based on multidimensional liquid chromatography coupled to MS (LC-MS/MS). 
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Fig. 2. Schematic workflow in 2D-DIGE plasma analysis. Isolation and processing of plasma 
samples 2D-DIGE analysis (left). 2D-DIGE of processed plasma samples using the 
combinatorial peptide ligand libraries (CPLL) (proteominer) (center) and depletion of most 
abundant plasma protein with affinity columns (right). 
Electrospray ionization (ESI) development and recent advances in mass spectrometry (MS) 
provided the second-generation of proteomics technology based on LC-MS/MS. This 
approach is nowadays referred to as shotgun proteomics or MudPIT (Chen EI et al., 2006 
and MacCoss MJ et al., 2002). To perform differential expression analysis , several probes 
have been designed for labeling both at protein and peptide levels (ICAT (isotope-coded 
affinity tagging), SILAC (stable isotope-labeling with amino acids in cell culture) or iTRAQ 
(stable isotope-tagged amine-reactive Reagents)) (Wu WW et al., 2006 and Graumann J et al., 
2008).  
iTRAQ is an LC-based methodology which is gradually gaining in popularity. iTRAQ 
reagents have permitted relative expression measurements of large sets of proteins with a 
high grade of automation. The isobaric nature of the tags allows the peptide samples to be 
pooled postlabeling, without increasing the complexity of MS analysis. Identical peptides 
labeled with the different iTRAQ reagents exhibit the same parent ion in MS. Upon MS/MS 
fragmentation of parent ion, unique signature ions are generated which distinguish the 
individual samples and, hence, the relative abundance among the samples can be 
determined (Figure 3). 
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Fig. 3. Schematic workflow of iTRAQ labeling: After denaturation, reduction, alkylation, 
and digestion, each protein sample is modified with a distinct iTRAQ ® reagent. The iTRAQ 
®-modified samples are then mixed to be analyzed by mass spectrometry. The MS/MS 
spectra of the individual peptides show signals reflecting amino acid sequences and also 
show reporter ions reflecting the protein contents of the samples. 
In a different approach, the low molecular weight fraction can be investigated (plasma 
peptidome) by LC-MS/MS or by Matrix-Assisted Laser Desorption/Ionization-mass 
Spectrometry (MALDI-MS). The peptidome has been described as all peptides that have 
been expressed in any cell, tissue, or biofluid at any given time (Schulte I et al., 2005 and 
Schrader M and Schulz-Knappe P, 2001). Peptidomics holds considerable promise for the 
discovery of new bioactive molecules and for elucidating biochemical regulatory networks. 
Endogenous peptides have already been established as messengers, hormones or cytokines 
in many physiological processes. Alterations in peptide levels under disease conditions 
implicate this class of molecules as potential biomarkers.  
Ultrafiltrates of plasma have been recognized for several years to contain complex mixtures 
of thousands of peptides that are smaller than apolipoprotein C-I, the smallest major plasma 
protein. The complete set of small peptides from plasma has been termed the plasma 
peptidome, or the fragmentome (Tirumalai R S et al., 2003) because it has been recognized 
that most small peptide components of plasma are derived from proteolytic degradation of 
larger proteins. Peptide fragments of many major plasma proteins, such as fibrinogen, 
apolipoproteins, transthyretin, and complement factors, have been detected (Adkins JN et 
al., 2002, Tirumalai RS et al., 2003 ). To obtain the plasma peptidome some authors have 
applied molecular weight filters (ranging 10-3,5kDa) to isolate small proteins and whole 
peptidome. With the focus on peptides rather than proteins, a hydrophobic-based capture 
technique, which removes salts and other hydrophilic compounds in a single step, is more 
compatible with direct LC-MS analysis (Zhou H et al., 2006 and Tian R et al., 2007).  
Some biochemical studies in AS plasma samples using the ELISA technique have reported 
alterations in their proteins levels. Most of these studies were focused in proteins implicated 
in cardiovascular diseases outstanding the natriuretic peptide (Yandle TG et al., 1986; Yandle 
TG et al., 1993 and  Hunt PJ. et al., 1997) whose  levels are prognostic of cardiovascular 
outcomes independently (26, Tsutamoto T. et al 1997). Recently, Qi W et al., 2001, Prasad N et 
al., 1997 and Talwar S et al., 2001. published that plasma natriuretic peptide levels were 
related to disease severity in AS. In addition, they also reported that cardiothrophin-1 (CT-1) 
levels were increased in AS patients and these results correlated with the trans-valvular 
aortic pressure gradient (TVPG) and could potentially be used to monitor progression of 
disease in a non-invasively manner. Ferrari G. et al have recently shown that individuals 
with severe AS exhibited higher plasma levels of NT-proBNP, BNP fragment, and 
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osteopontin compared with controls. Fetuin-A levels were lower in individuals with AS 
than in healthy controls. Asymmetric dimethylarginine (ADMA) were lower while 
homocysteine levels were higher in theAS patients. 
Despite the potential offered by proteomics, plasma from AS patients has not been studied, 
until now. Taking into account the studies performed with one protein or with a small 
number of proteins, a proteomic plasma analysis, without bias, could give us a more 
complete sight at molecular level of this pathology and its possible relation with 
atherosclerosis. The HUPO Plasma Proteome consortium has identified a group of 345 
cardiovascular-related proteins that could constitute a baseline proteomic blueprint for the 
future development of biosignatures for cardiovascular diseases (Vivanco, F. et al. 2007). 
Hence, new studies focusing in plasma from AS patients will be necessary to deepen in this 
pathology, in order to find new biomarkers and therapies. 
3. Tissue, isolated cells and secretome 
Protein tissue biomarkers offer a great promise to provide a clinical diagnosis and prognosis 
information that cannot be obtained from genomics or serum biomarkers. In the past, the 
discovery phase has been delayed by several hurdles including tissue heterogeneity and the 
lack of sensitive technology to identify and measure protein in small volumes of human 
biopsy tissue (Espina et al., 2009). These hurdles have been largely overcome by the wide 
availability of laser microdissection technology, protein microarrays, and advances in mass 
spectrometry (Emmert-Buck et al., 1996; Petricoin et al., 2005). Under such considerations, 
the tools and methodology of proteomics are becoming increasingly important and, we 
could postulate that tissue proteomics studies provide us two main information data sets: 1) 
potential biomarkers of disease directly released from tissue lesions, which should be 
validated in wider cohorts before being applied to clinics; 2) discovery of action mechanisms 
and pathways involved in the formation and development of AS by direct “in-situ” 
proteomics (Alvarez-Llamas et al., 2007).  
3.1 Stability in tissue: pre-analitycal variability 
Today, there is an important need to develop standardized protocols and novel technologies 
that can be used in the routine clinical settings for seamless collection and immediate 
preservation of tissue in the search for biomarker proteins. In this sense, both clinicians and 
researcher are implicated. The fidelity of the data obtained from a diagnostic assay applied 
to the tissue must be monitored and quality controlled. Under the current standard of care, 
AS tissue is procured by AS replacement in a hospital-based operating room. The instant a 
tissue biopsy is removed from a patient, the cells within the tissue react and adapt to the 
absence of vascular perfusion, ischemia, hypoxia, acidosis, accumulation of cellular waste, 
absence of electrolytes and temperature changes (Espina et al., 2008). Normally tissue is 
frozen in dry ice or liquid nitrogen or fixed to avoid degradation and to preserve for later 
proteomics analysis. Otherwise, the tissue is maintained in physiological serum if we want 
to develop secretome analysis. A multitude of known and unknown variables can influence 
the stability of AS tissue molecules: temperature, pH, hypoxia, dehydration, RNAses 
activity, proteinases activity, ex-vivo stress (Espina et al., 2008) etc. For these reasons the 
protocol to follow must be the strictest as possible: The recommended maximum elapsed 
time ranges between 20 minutes to 2 hours from surgery to stabilization (freezing, tissue 
culture, fixation, etc.). Finally, the study of tissue can be addressed according to three main 
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sample sources: a) whole tissue proteomics, by which total proteins extracts obtained from 
areas of interest are studied; b) tissue sub-proteomes, i.e. specific aortic valve layers and 
cells isolated directly from tissue (apart from those studies based on cultured cells); c) tissue 
secretome, which is a media enriched in proteins that derive from diseased tissue and, 
therefore, one of the best sources for biomarker discovery. 
3.2 Whole tissue 
Different techniques were applied to human samples from shotgun proteomics or 2-DE to 
antibody arrays and MS Imaging. In the case of AS valves tissue proteomics analysis, the 
main tools employed until now are the 2-DE and the 2D-DIGE. Focus on the aim of 
maximizing the number of extracted proteins, AS valves must be processed following a 
“strong” and sequential extraction protocol (Gil-Dones et al., 2010). The first step relies on a 
strong lysis buffer in which most of the soluble proteins are extracted, and the second was 
designed to extract the membrane and hydrophobic proteins. It is important to note that one 
of the most important problems associated with proteomic analyses of AS valves is the high 
concentration of calcium that interferes with further analyses.  For this reason the extracts 
must be desalting (Gil- Dones et al., 2010). Our group found that approximately 500 spots 
were well resolved in IPG strip of pH4-7 when compared with the 350 spots evident from 
the pH 3-10 strip, by 2-DE. Attending to 2D-DIGE, 1346 spots were detected. Significantly, 
the protein extraction protocol was compatible with both methods. The improvement in 
sensitivity associated with the 2D-DIGE technology with respect to 2-DE was clearly 
evident. We conclude that the use of fluorescent labeling and Decyder analysis software 
considerably increases the number of protein spots that can be detected in the analysis when 
compared to more traditional methods (Gil-Dones et al., 2010). 
In this sense, Matt P et al, 2007 studied aortic aneurysm associated with bicuspid (BAV) and 
tricuspid aortic valve (TAV) using 2-DE and mass spectrometry (MS). Few proteins showed 
significant differences, among these a phosphorilated form of HSP27 with significantly 
lower expression in BAV compared to TAV aortic samples. The phosphoprotein tracing 
revealed four different phosphoproteins including Rho GDP dissociation inhibitor, calponin 
3, myosin regulatory light chain 2 and 4 phosphorilated forms of HSP27. Western blot 
analyses were made to validate the results obtained by proteomics analysis. 
Following the same approach, mitral valves of chronic rheumatic heart disease (RHD) 
patients were studied by  Fae KC et al., 2008, identifying three proteins recognized by heart 
infiltrating and peripheral T cells as protein disulfide isomerase ER-60 precursor, 78kDa 
glucose-regulated protein precursor and vimentin. These proteins were recognized in a 
proliferation assay by peripheral and heart infiltrating T cells from RHD patiens suggesting 
that they may involved in the autoimmune (Fae et al. 2008).  
In a different approach, antibody array technology has experienced an important advance in 
the latest times. Commercially pre-arrayed platforms in diverse research areas are 
nowadays available, but only one study has been recently reported applying commercial 
antibody arrays to atherome plaque extracts (Slevin et al., 2006). 
3.3 Aortic stenosis sub-proteomes 
Within the stenotic aortic valve coexists several cell types, mainly valvular fibroblasts or 
interstitial cells (VICs), endothelial cells (ECs), macrophages/foam cells and T-lymphocytes. 
Aortic valve tissue studies constitute a very valuable tool in the search for alterations and 
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Fig. 4. Schematic diagram illustrating the methodology used for the proteomics analysis of 
aortic valve tissue. 
disease specific biomarkers which would shed light on the understanding of AS and 
contribute to its early diagnosis. However, sub-fractionation of the aortic valve tissue in its 
structures or cellular components seems to be a complementary strategy to whole tissue 
analysis, in order to determine the specific contribution of those cells/structures in the 
pathogenesis of AS. Concretely, in the field of Proteomics, protein alterations observed in 
whole tissue samples may benefit from complementary assays involving localization of 
these proteins in the tissue, such as immunostaining techniques. Although the proteomic 
analysis of the different sub-fractions from the aortic valve tissue may represent a 
noteworthy strategy for AS research, this field remains almost unexplored. Strategies 
involving the combination of aortic valve tissue sub-fractionation and proteomic analysis of 
these sub-proteomes will be therefore discussed. 
3.3.1 Laser microdissection 
The different structures from a histology section of a tissue can be isolated by means of 
microscopical dissection. In this case, manual microdissection may be applied with the use 
of a microscopical needle under an optical microscope. However, laser microdissection 
(LMD), first described in 1996 (Emmert-Buck et al., 1996), is a more accurate technique for 
the isolation of tissue regions, cells or even subcellular fractions. This first method, called 
laser capture microdissection (LCM), involved irradiation with a laser beam of a 
thermoplastic membrane in contact with the tissue. Since the heating of the tissue during 
microdisecction contributes to protein degradation, newly developed laser cutting 
techniques may be more adequate to implement in a proteomic workflow.  
Even though laser microdissection is an outcoming methodology which has been applied in 
several cardiovascular studies, involving cardiac (De Souza et al., 2004; Chimenti et al., 2004; 
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Kuhn et al., 2006, 2007; Roy et al. 2006; Grube et al., 2006; Pan et al., 2008) and arterial tissue 
(Stolle et al., 2004; Chimenti et al., 2010; Kwapiszewska et al., 2005; Bagnato et al., 2007; 
Ciervo et al., 2008; Okami et al., 2009; De la Cuesta et al., 2009, 2011), it has been only used to 
date for the analysis of valvular tissue in a rat model of pharmacologically-induced 
valvulopathy (Elangbam et al., 2008). Furthermore, its combination with proteomic 
methodologies may yield interesting results, in the same way that has been proven in other 
cardiovascular tissue samples (De Souza et al., 2004; Bagnato et al., 2007; De la Cuesta et al., 
2009, 2011). The principal challenge in the combination of LMD with Proteomics, is the 
scarce amount of protein that can be obtained from laser-microdissected tissue, since no 
long microdissection periods should be applied in order to avoid protein degradation. 
Nowadays, mass spectrometers can deal with scarce amounts of sample due to an 
exponential improvement in their sensitivity, therefore facilitating the analysis by LC-
MS/MS of laser-microdissected tissue. On the other hand, the use of fluorescent labels such 
as the CyDyes from the DIGE Fluor Labeling Kit for Scarce Samples (GE Healthcare) allowed 
analyzing protein extracts from LMD-isolated structures/cells by means of two-dimensional 
electrophoresis. These dyes label through saturation the cystein residues from the proteins 
in the mixture and allow running 2-DE gels with less than 5µg of total protein (Sitek et al., 
2005). Since protein identification by MS of the spots in such gels is only possible with most 
abundant spots, these identifications can be performed using pooled samples from LMD or 
a reference proteome, which may be the one from the whole tissue microdissected (Kondo & 
Hirohashi, 2007). 
The application of LMD to the analysis of the aortic valve tissue could provide specific data 
from the different layers/structures in the tissue, as well as from the behavior of the 
different cells in the stenotic milieu. In addition, its combination with a proteomic workflow 
may constitute a step forward in the understanding of the role played by the different cells 
involved in AS pathogenesis and in the search for novel tissue biomarkers of this pathology. 
3.3.2 Living cells isolation 
An alternative methodology to simplify tissue complexity and to study its cellular 
components is to enzymatically digest the tissue and separate the cells for subsequent 
analysis. This can be done by cell sorting methodologies or by specific explant culturing. In 
the first one, specific cell populations can be separated in a flow-cytometer and directly 
analyzed by proteomic techniques. The main problem in this workflow would be the high 
amount of tissue necessary to obtain enough cells for a proteomic analysis, which sometimes 
is impossible to extract, especially when dealing with biopsy material. Culturing sorted cells 
is an option, but constitutes a more complicated approach than explants culturing, since 
sorted cells may be damaged in the cytometer, which involves lesser sub-culturing capacity. 
In contrast, non-sorted cell suspensions should be cultured under specific conditions to 
favor a certain cell type, which sometimes may imply contamination by other cells.  The 
main drawback of sub-culturing methodologies is that the cells may lose its in vivo 
phenotype within the culture, since the environmental conditions are completely altered in 
the in vitro situation. Nevertheless, cell cultures allow setting very strictly experimental 
parameters in order to diminish variation between replicates, and analyzing cells responses 
to different stimuli, which turns them into a very useful tool for proteomic analysis. For 
such purposes, the methodology called stable isotope labeling with aminoacids in cell culture 
(SILAC) (Ong et al., 2002), constitutes a valuable approach to analyze both proteome and 
secretome of the different subset of aortic valve cells by means of differential LC-MS/MS. 
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Fig. 5. Scheme of a proteomic workflow for the analysis of AS valve tissue sub-proteomes. 
An additional step in the sub-fractionation of the tissue would be to isolate cell 
structures/organelles. Conventional ultracentrifugation can be applied to separate 
membranes, nuclei and cytosolic fractions for subsequent proteomic analysis (Huber et al. 
2003). Using this approach, membrane and cytosolic proteins from Pro-calcific VICs after 
lipopolysaccharide (LPS) treatment were compared to non-treated ones by 2-DE (Bertacco et 
al., 2010), in which constitutes the first proteomic study performed with cells isolated from 
aortic valves. On the other hand, cellular organelles and vesicles, like mithocondrias, Golgi 
stacks and vesicles or endosomes, are efficiently separated by density gradient 
centrifugation (Huber et al. 2003). Concerning secreted vesicles (microparticles, exosomes…), 
ultracentrifugation, either under density gradient or not (Van der Pol et al., 2010), constitutes 
the easiest methodology to set up and to combine with proteomic analysis.  
As far as we step forward in sub-fractionating cells proteome, the further the decrease on 
protein recovery will go. For this reason, while designing the strategy of a proteomic study, 
we should take into account the balance between the number of sub-fractionation steps and 
the amount of protein recovered. 
3.3.3 Secretome 
The term secretome comprises the sub-set of proteins that are actively released by cells or 
tissue in the extracellular compartment as consequence of the normal metabolism or in 
response to some stimuli. As such, it is a powerful source of key molecules involved in 
www.intechopen.com
 
Aortic Stenosis – Etiology, Pathophysiology and Treatment 
 
178 
pathogenesis development, individual response to pharmacological intervention or recovery 
status. Secretome studies are increasing in the last years as it provides an accurate model of 
the in vivo situation and it represents a sub-proteome of serum/plasma, showing a much 
narrower proteins concentrations dynamic range which enormously facilitates detection of 
minor proteins whose identification is otherwise obscured by high-abundance plasma 
proteins.  Plasma, serum and urine are traditional sample sources for biomarker discovery, 
as they are easily and commonly obtained in clinical practice; however, secretome-based 
research will favor the detection of novel proteins or, at least, known molecules with new 
implications in the disease under study. Most studies are focused on the secretome obtained 
from in vitro cell cultures, assuming that such cells’ behavior well simulates the in vivo 
condition (Roelofsen et al., 2009). In particular, the cancer secretome, namely the whole 
collection of proteins secreted by cancer cells through various secretory pathways, has 
recently been shown to have significant potential, as secreted proteins might represent 
putative tumor biomarkers or therapeutic targets (Karagiannis et al., 2010). The most perfect 
approximation to the real situation is the study of the in vivo secretome.  In this research line, 
one of the few proteomics studies was carried out by implanting capillary ultrafiltration 
probes into tumor masses induced in mice (Alvarez-Llamas et al., 2007; Hocking et al., 2010). 
However, this is not always feasible and the use of tissue explants (ex vivo approach) 
represents a compromise solution which gives information about secretory molecules 
coming from all tissue components as result of cross-talk between them and approaches the 
physiological situation better than the cell culture. Adipose tissue secretome was 
investigated as a tissue model representing not only energy storage depot but, more 
importantly, a key organ for the regulation of energy metabolism through secretion of a 
variety of adipokines involved in the regulation of energy metabolism (Roelofsen et al., 2009; 
Hocking et al., 2010). Two key points to consider when working directly with tissue in 
culture are: a) the need to ensure that all detected proteins are truly coming from the tissue 
and not “contaminants” derived from plasma and b) validation of identified proteins as 
secreted. A metabolic labelling approach allows differentiation between proteins 
synthesized by the tissue (labelled) and contaminating proteins from blood which remain 
unlabelled (Alvarez-Llamas et al., 2007). In this sense, an optimized culture protocol should 
be developed to maximize label incorporation into proteins including a series of medium 
changes during the initial hours of culture, followed by an extended step of tissue culture. In 
any case, label incorporation is influenced by the rate of synthesis of each particular protein, 
which may condition the number of labelled proteins that can be detected at a particular 
time point. Incorporation of the label by a protein validates tissue origin but does not 
necessarily imply “intentional” secretion. Once synthesized by the tissue, the release of a 
protein into the media could be attributed to damage-induced tissue leakage and results in 
detection of intracellular proteins. One can assume that it is very challenging to totally avoid 
the presence of intracellular proteins, as cell lysis always takes place during cell/tissue 
culture. However, optimum culture conditions may favor secreted proteins enrichment. 
Classification of identified proteins as secreted ones is usually done by computational 
methods: classically secreted proteins (via the ER-Golgi pathway) can be predicted as 
containing a signal peptide by SignalP (Bensten JD, et al., 2004) or being classified as 
extracellular via Gene Ontology analysis; non-classically secreted proteins, which do not 
contain N-terminal signal peptide, can be predicted by SecretomeP ( Bendsten JD, et al., 
2004) and more recently by SecretP (Yu et al., 2010). 
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The aortic valve secretome is therefore an attractive target to further understand the AS 
pathogenic process, while revealing mechanisms in common to atherosclerosis. The study of 
atherosclerotic plaque secretome in the search of potential biomarkers of atherosclerosis has 
been reported (Duran et al., 2007; Duran et al., 2007), finding that HSP-27 release was 
decreased in atherosclerotic plaques and barely detectable in complicated plaques 
supernatants. Further validation and feasible detection in biological fluids should follow 
prior to the use of discovered proteins as markers of diagnosis or prognosis. In this case, 
circulating concentrations of HSP27 were found to be decreased in subjects with 
atherosclerosis compared to healthy subjects, which confirms the hypothesis that plasma 
content can reflect arterial wall secretion (Martin-Ventura et al., 2004). Effects of atorvastatin 
treatment on atherosclerotic plaque secretion was also investigated, finding that 66% of the 
proteins differentially released by atherosclerotic plaques reverted to control values after 
administration, in particular, cathepsin D which becomes a potential target for therapeutical 
treatment (Duran et al., 2007). Recent studies carried out in our laboratory point to a sub-set 
of proteins which are differentially released by healthy arteries in comparison to 
atherosclerotic coronary ones [submitted for publication] and whose role in AS 
development is currently ongoing. In Figure 4 a proposal for AS secretome obtention and 
proteomic analysis is shown. 
 
 
Fig. 6. Secretome from tissue explants is an ex-vivo approach with enormous potential as 
biomarkers source. It is key to validate proteins origin by i.e. label inclusion at protein level 
and secretion patterns by available softwares. 
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4. Conclusions 
Recently, cardiovascular proteomics has experienced an impressive development. At 
present, hundreds of proteins have been associated with cardiovascular diseases using 
proteomic approaches and different kinds of biological samples. The proteomic approaches 
allow to explore the expression of multiple proteins at once, giving us the opportunity to 
know which proteins are involved in pathophysiologic process of degenerative aortic 
stenosis in order to unveil the basic mechanisms of this disease. Most probably, these novel 
approaches will facilitate the study of this pathology and disclose diagnostic markers and 
multiple potential targets for the design of more powerful and personalized therapies. 
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